New York State Teachers Retirement System Has $2.15 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

New York State Teachers Retirement System trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,650 shares of the company’s stock after selling 329 shares during the period. New York State Teachers Retirement System owned approximately 0.05% of Krystal Biotech worth $2,151,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of KRYS. CWM LLC grew its holdings in shares of Krystal Biotech by 7.2% during the 2nd quarter. CWM LLC now owns 1,583 shares of the company’s stock worth $218,000 after purchasing an additional 107 shares in the last quarter. Aberdeen Group plc lifted its position in Krystal Biotech by 190.9% in the second quarter. Aberdeen Group plc now owns 108,518 shares of the company’s stock worth $14,917,000 after purchasing an additional 71,217 shares during the period. Vontobel Holding Ltd. boosted its stake in Krystal Biotech by 13.9% during the second quarter. Vontobel Holding Ltd. now owns 3,075 shares of the company’s stock worth $423,000 after buying an additional 375 shares in the last quarter. Maryland State Retirement & Pension System increased its holdings in Krystal Biotech by 1.7% in the 2nd quarter. Maryland State Retirement & Pension System now owns 7,474 shares of the company’s stock valued at $1,027,000 after buying an additional 123 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Krystal Biotech by 15.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,116 shares of the company’s stock valued at $153,000 after buying an additional 152 shares during the period. Institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on KRYS. Bank of America raised their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research report on Friday. Finally, Chardan Capital decreased their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a research note on Friday, August 22nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $223.00.

Krystal Biotech Trading Down 2.6%

NASDAQ KRYS opened at $190.78 on Wednesday. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The company has a 50 day moving average of $162.81 and a 200-day moving average of $151.55. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of 38.78 and a beta of 0.64.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).